UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice

The Journal of clinical investigation, 2009-07, Vol.119 (7), p.2086-2099

2009

Volltextzugriff (PDF)

Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices

Thrombosis research, 2013-08, Vol.132 (2), p.e161-e163

2013

Volltextzugriff (PDF)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Therapeutic advances in hematology, 2023-01, Vol.14, p.20406207231166779-20406207231166779

2023

Volltextzugriff (PDF)

Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey

Journal of multidisciplinary healthcare, 2012-01, Vol.5 (default), p.277-287

2012

Volltextzugriff (PDF)

Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing

Blood coagulation & fibrinolysis, 2014-04, Vol.25 (3), p.232-236

2014

Volltextzugriff (PDF)

Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia

European journal of haematology, 2012-10, Vol.89 (4), p.361-364

2012

Volltextzugriff (PDF)

Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study

JMIR medical informatics, 2021-11, Vol.9 (11), p.e30743-e30743

2021

Volltextzugriff (PDF)

Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients

Haematologica (Roma), 2007-08, Vol.92 (8), p.1029-1036

2007

Volltextzugriff (PDF)

Hemophilic Arthropathy of the Elbow

Hand clinics, 2011-05, Vol.27 (2), p.151-163

2011

Volltextzugriff (PDF)

Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects

Thrombosis and haemostasis, 2000-10, Vol.84 (4), p.643-652

2000

Volltextzugriff (PDF)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

Research and practice in thrombosis and haemostasis, 2019-07, Vol.3 (3), p.528-541

2019

Volltextzugriff (PDF)

Improved Bleeding Outcomes in Patients Who Switched From Sucrose-Formulated rFVIII to BAY 94-9027 Prophylaxis in PROTECT VIII

Blood, 2020-11, Vol.136 (Supplement 1), p.6-7

2020

Volltextzugriff (PDF)

Use of recombinant human antithrombin concentrate in pregnancy

International journal of women's health, 2013-01, Vol.5 (default), p.583-586

2013

Volltextzugriff (PDF)

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

The New England journal of medicine, 2022-03, Vol.386 (11), p.1013-1025

2022

Volltextzugriff (PDF)

Acquired Von Willebrand Disease – To Treat Or Not To Treat The Inhibitor?

Blood, 2013-11, Vol.122 (21), p.4744-4744

2013

Volltextzugriff (PDF)

Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival

Bone marrow transplantation (Basingstoke), 2015-11, Vol.50 (11), p.1432-1437

2015

Volltextzugriff (PDF)

Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation

Biology of blood and marrow transplantation, 2018-12, Vol.24 (12), p.e20-e25

2018

Volltextzugriff (PDF)

Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study

Blood, 2022-11, Vol.140 (Supplement 1), p.5612-5614

2022

Volltextzugriff (PDF)

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Blood, 2022-11, Vol.140 (Supplement 1), p.11360-11361

2022

Volltextzugriff (PDF)

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

Blood, 2021-11, Vol.138 (Supplement 1), p.2115-2115

2021

Volltextzugriff (PDF)

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Blood, 2018-11, Vol.132 (Supplement 1), p.1206-1206

2018

Volltextzugriff (PDF)

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Blood, 2018-11, Vol.132 (Supplement 1), p.2492-2492

2018

Volltextzugriff (PDF)

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Blood, 2019-11, Vol.134 (Supplement_1), p.1129-1129

2019

Volltextzugriff (PDF)

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Blood, 2019-11, Vol.134 (Supplement_1), p.4943-4943

2019

Volltextzugriff (PDF)

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies

American journal of hematology, 2022-05, Vol.97 (5), p.519-526

2022

Volltextzugriff (PDF)

26 – 50 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(134)

Publikationsform

Sprache

Englisch
(147)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice

Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey

Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing

Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia

Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study

Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients

Hemophilic Arthropathy of the Elbow

Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

Improved Bleeding Outcomes in Patients Who Switched From Sucrose-Formulated rFVIII to BAY 94-9027 Prophylaxis in PROTECT VIII

Use of recombinant human antithrombin concentrate in pregnancy

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

Acquired Von Willebrand Disease – To Treat Or Not To Treat The Inhibitor?

Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival

Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation

Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies

Suchergebnisse filtern